既往较为难治的HER2+和三阴性乳腺癌分型预后均得到显著改善。在新型药物不断发展和临床研究逐渐进步的情况下,临床实践中观察到HR+/HER2-早期乳腺癌与其他分型乳腺癌的预后差异逐渐缩小,其预后仍有很大的改善空间。 一方面,随着对HR+/HER2-乳腺癌复发风险的深入研究,此类患者的复发风险不容忽视。有研究显示约40%接...
HER2‐negative, node‐positive, high‐risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open‐label, phase 3 trial. Lancet Oncol. 2022;0(0):77‐90.
乳腺癌是一种在分子水平上具有高度异质性的肿瘤,包括多种组织学类型和分子亚型,因此显示出不同的表型和基因型差异,并且对治疗的反应以及预后也有很大不同1。激素受体阳性(HR+)乳腺癌是最常见的乳腺癌亚型,约…
[14]REGAN M M, FRANCIS P A, PAGANI O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapy for premenopausal women with HR+ HER2-negative breast cancer: results from TEXT and ...
HR+/HER2- 是乳腺癌最常见的亚型,约占新发乳腺癌的 70%[1]。近年来,CDK4/6 抑制剂的出现让 HR+/HER2- 乳腺癌的治疗全面进入了靶向联合内分泌时代。其中瑞波西利作为能为全人群(绝经前/围绝经期、绝经后患者)HR+/HER2- 晚期乳腺癌患者带来显著生存获益的 CDK4/6 抑制剂,
(PS, censoring at the start of the maintenance ET and considering ET as a time-dependent variable) to overcome potential biases. All these analyses showed very similar results indicating that initial treatment with ET improves survival in patients with HR-positive HER2-negative MBC, as compared ...
The clinical effectiveness of three common genetic testing methods including OncotypeDX, MammaPrint and PAM50 on the patients of HR⁃positive and human epidermal growth factor receptor 2 ( human epidermal growth factor receptor 2, HER2) negative in early invasive breast cancer will be reviewed in ...
[1] Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023 Sep 8;9(1):74. [2] Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistan...
[1] Ma J, Chan JJ, Toh CH, Yap YS. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 2023 Sep 8;9(1):74. [2] Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistan...
王磊苹教授还提到,值得注意的是,这些试验纳入的中国患者的pCR率相较于整体人群偏低。因此,对于HR+/HER2-乳腺癌新辅助免疫治疗的问题,仍需要更多中国人群的研究数据。 报告最后,王磊苹教授进行了总结,她表示,HR+/HER2-乳腺癌新辅助治疗还未进入免疫治疗时代。但免疫治疗在早期HR+/HER2-乳腺癌治疗领域已经取得了治疗...